Cover Image

First-in-human brain imaging of [18F]TRACK, a PET tracer for tropomyosin receptor kinases

The tropomyosin receptor kinase TrkA/B/C family is responsible for human neuronal growth, survival, and differentiation from early nervous system development stages onward. Downregulation of TrkA/B/C receptors characterizes numerous neurological disorders including Alzheimer’s disease (AD). Abnormal...

Full description

Saved in:
Bibliographic Details
Main Authors: Bailey, Justin (Author) , Kaiser, Lena (Author) , Lindner, Simon (Author) , Wüst, Melinda (Author) , Thiel, Alexander (Author) , Soucy, Jean-Paul (Author) , Rosa-Neto, Pedro (Author) , Scott, Peter J. H. (Author) , Unterrainer, Marcus (Author) , Kaplan, David R. (Author) , Wängler, Carmen (Author) , Wängler, Björn (Author) , Bartenstein, Peter (Author) , Bernard-Gauthier, Vadim (Author) , Schirrmacher, Ralf (Author)
Format: Article (Journal)
Language:English
Published: 2019
In: ACS chemical neuroscience
Year: 2019, Volume: 10, Issue: 6, Pages: 2697-2702
ISSN:1948-7193
DOI:10.1021/acschemneuro.9b00144
Online Access:Verlag, Volltext: https://doi.org/10.1021/acschemneuro.9b00144
Get full text
Author Notes:Justin J. Bailey, Lena Kaiser, Simon Lindner, Melinda Wüst, Alexander Thiel, Jean-Paul Soucy, Pedro Rosa-Neto, Peter J.H. Scott, Marcus Unterrainer, David R. Kaplan, Carmen Wängler, Björn Wängler, Peter Bartenstein, Vadim Bernard-Gauthier, and Ralf Schirrmacher
Description
Summary:The tropomyosin receptor kinase TrkA/B/C family is responsible for human neuronal growth, survival, and differentiation from early nervous system development stages onward. Downregulation of TrkA/B/C receptors characterizes numerous neurological disorders including Alzheimer’s disease (AD). Abnormally expressed Trk receptors or chimeric Trk fusion proteins are also well-characterized oncogenic drivers in a variety of neurogenic and non-neurogenic human neoplasms and are currently the focus of intensive clinical research. Previously, we have described the clinical translation of a highly selective and potent carbon-11-labeled pan-Trk radioligand and the preclinical characterization of the optimized fluorine-18-labeled analogue, [18F]TRACK, for in vivo Trk positron emission tomography (PET) imaging. We describe herein central nervous system selectivity assessment and first-in-human study of [18F]TRACK.
Item Description:Gesehen am 26.09.2019
Publication date: April 24, 2019
Die 18 im Titel ist hochgestellt
Physical Description:Online Resource
ISSN:1948-7193
DOI:10.1021/acschemneuro.9b00144

Similar Items